CHARTER GUIDEWIRE MODEL 45-281, 45-282, 45-283

K103377 · Brivant, Ltd. · DQX · May 18, 2011 · Cardiovascular

Device Facts

• Record ID: K103377
• Device Name: CHARTER GUIDEWIRE MODEL 45-281, 45-282, 45-283
• Applicant: Brivant, Ltd.
• Product Code: DQX · Cardiovascular
• Decision Date: May 18, 2011
• Decision: SESE
• Submission Type: Special
• Regulation: 21 CFR 870.1330
• Device Class: Class 2

Intended Use

The Charter™ Guidewires are intended for use in the coronary and peripheral vasculature. Contraindications: The Charter™ Guidewire is not intended for use in the cerebral vasculature. Patients judged not acceptable for percutaneous intervention (PCI).

Device Story

Charter Guidewire is a single-use, disposable device designed to facilitate navigation of catheters through coronary and peripheral vasculature. The device consists of a stainless steel core wire (140cm or 180cm length; 0.014" or 0.018" diameter) with a centerless-ground tapered distal section for variable stiffness. The distal tip features a platinum-tungsten spring coil for radiopacity and an Estane 88A polymer sleeve. The wire is coated to enhance lubricity. Operated manually by a physician during percutaneous intervention (PCI), the guidewire acts as a track for catheter advancement. The radiopaque tip allows visualization under x-ray, assisting the physician in precise placement within the vasculature. By providing a stable path, the device enables the delivery of therapeutic or diagnostic catheters, potentially improving procedural success and patient outcomes in vascular interventions.

Clinical Evidence

Bench testing only. No clinical data provided. Performance evaluations included tensile strength, torque strength, outer diameter measurement, torque response, catheter compatibility, coating adherence/integrity, and tip flexibility. Biocompatibility testing was conducted in compliance with ISO 10993-1, including cytotoxicity, irritation, acute systemic toxicity, and comprehensive haemocompatibility assays (haemolysis, coagulation, thrombosis, and complement activation).

Technological Characteristics

Materials: Stainless steel core, platinum-tungsten spring coil, Estane 88A radiopaque heat shrink polymer tubing. Dimensions: 140cm/180cm length, 0.014"/0.018" diameter. Principle: Manual guidewire for catheter tracking. Features: PTFE coating, hydrophilic coating, centerless-ground tapered core. Biocompatibility: ISO 10993-1 compliant. Sterilization: Not specified.

Indications for Use

Indicated for use in coronary and peripheral vasculature. Contraindicated for cerebral vasculature and patients ineligible for percutaneous intervention (PCI).

Regulatory Classification

Identification

A catheter guide wire is a coiled wire that is designed to fit inside a percutaneous catheter for the purpose of directing the catheter through a blood vessel.

Special Controls

*Classification.* Class II (special controls). The device, when it is a torque device that is manually operated, non-patient contacting, and intended to manipulate non-cerebral vascular guide wires, is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 870.9.

Predicate Devices

• Brivant Guidewire (K060551)
• Streamer Guidewire (K083094)
• Courier Guidewire (K073082)

Submission Summary (Full Text)

{0}------------------------------------------------

Image /page/0/Picture/0 description: The image shows the logo for Lake Region Medical. The logo consists of a stylized graphic above the words "Lake Region" in a bold, sans-serif font. Below "Region" is the word "Medical" in a smaller font size with a small solid circle to the right of the word.

# K103377

Navilyst Charter 510(k) Application

## 510(k) Summary

## as required by 21 CFR 807.92(c)

| Device Name | Charter™ Guidewire | | |
|---------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------|--------------|
| Submitters<br>name/contact<br>details | Brivant Ltd,<br>Parkmore West Business Park,<br>Galway,<br>Ireland<br><br>Contact Details:<br>Tomas Furey<br>Operations Manager,<br>Tel: [phone]<br>Fax: [phone] | | |
| Summary<br>Preparation Date | 10th November 2010 | | |
| Device Name &<br>Classification | Trade Name: Charter™ Guidewire<br>Common Name: Guidewire<br>Classification Name: Catheter, Guidewire<br>Device Classification: Class II, 21 CFR §870.1330<br>Product Code: DQX | | |
| Intended Use | Intended Use:<br>The Charter™ Guidewires are intended for use in the coronary and peripheral<br>vasculature.<br><br>Contraindications:<br>The Charter™ Guidewire is not intended for use in the cerebral vasculature.<br>Patients judged not acceptable for percutaneous intervention (PCI) | | |
| Device Description | The Navilyst Medical Guidewire is a disposable medical device designed for<br>single use only. It consists of a PTFE coated 140cm or 180cm, 0.014" or 0.018"<br>diameter stainless steel core wire, one end of which is reduced in diameter over<br>a 43cm approx. segment in a progressive fashion through a centreless grinding<br>operation. The profile of this reduced section affords the product a reduced area<br>of stiffness and can be varied to produce various levels of support.<br><br>The distal part of the reduced section is covered with a 3cm, 0.010" platinum<br>tungsten spring coil. This provides greater visibility on x-ray equipment. A 39cm<br>approx. length of black / grey Estane 88A radiopaque heat shrink polymer tubing<br>is applied over the tapered distal end of the wire and ground to form a constant<br>outer diameter, OD, equivalent in diameter to the main core body.<br>Coatings are placed on the device to improve the lubricity and ease in its<br>advancement through the guide catheter and the blood vessel | | |
| Predicate Devices | Manufacturer | 510k | Date |
| | Brivant Ltd, Brivant Guidewire | K060551 | 07 Jun 2006 |
| | Brivant Ltd, Streamer Guidewire | K083094 | 07 July 2009 |
| | Brivant Ltd, Courier Guidewire | K073082 | 09 Jan 2008 |
| Principle of<br>Operation | The Charter™ Guidewire is operated manually by a manual process | | |
| Comparison of<br>Technological<br>Characteristics | The Charter™ wire has minor differences in construction to the approved Brivant<br>Guidewire. These include Same diameter range as predicate devices Same basic construction technology as the predicate devices. Different polymer and hydrophilic coating materials to the predicate devices providing improved radiopacity. Slightly shorter overall length than predicate devices. Minor differences in profiles of the distal tip area of the guidewire changes to meet customer performance requirements. These changes are within ranges of the predicate devices. | | |
| | In vitro bench testing was performed to support a determination of substantial equivalence (refer to performance testing below) between the Charter™ Guidewires (in its various configurations) and the predicate devices.<br>The results of these tests provide reasonable assurance that the proposed device has been designed and tested to assure conformance to the requirements for its intended use and performs comparably to the predicate devices. The differences in construction between the Charter™ wire and the predicate devices raise no new issues of safety and effectiveness such that the Charter™ Guidewire is considered substantially equivalent to the predicate devices. | | |
| Performance<br>Testing (non-clinical) | In vitro bench tests were carried out to demonstrate equivalence with reference to the FDAs guidance document "Coronary and Cerebrovascular Guidewire Guidance, Jan 1995".<br>The following bench tests were performed: Tensile Strength Torque Strength Outer Diameter measurement Torque Response Catheter Compatibility Coating Adherence/Coating Integrity Tip Flexibility The results from these performance evaluations demonstrated that the Charter™ Guidewire met the acceptance criteria defined in the product specification and performed comparably to the predicate device. | | |
| | Biological Safety of the device has been established through biocompatibility testing carried out in compliance with ISO 10993-1 under VP-0427<br>The following biocompatibility tests were performed | | |
| | <b>Test Description</b> | <b>Test Method</b> | |
| | Cytotoxicity Study | Qualitative Evaluation – Dye Exclusion &<br>Microscopial Evaluation | |
| | Cytotoxicity Study | Quantitative Evaluation - MTT or XTT Assay | |
| | Irritation Test | Intracutaneous Injection (ISO10993-10) | |
| | Acute Systemic Toxicity Test | Systemic Injection<br>ISO10993-11 | |
| | Acute Systemic Toxicity Test | ISO-Rabbit-Pyrogen | |
| | Haemocompatibility Test | Haematology: Haemolysis - rabbit blood- Direct<br>(Complete ASTM Method) | |
| | Haemocompatibility Test | Haematology:<br>In-vitro Haemocompatiblity Assay | |
| | Haemocompatibility Test | Coagulation: The Prothrombin Time Assay (PT) | |
| | Haemocompatibility Test | Coagulation: The Unactivated Partial<br>Thromboplastin Time Assay (UPTT) | |
| | Haemocompatibility Test | Thrombosis: In Vivo Thrombogenicity in Dogs | |
| | Haemocompatibility Test | Complement Activation | |
| | Haemocompatibility Test | Lee& White Coagulation Assay | |
| Conclusions | Based on safety and performance testing, technological characteristics and the | | |
| | indications for use for the device, the Charter™ Guidewire has been | | |
| | demonstrated to be appropriate for its intended use and is considered to be<br>substantially equivalent to the predicate devices. | | |

{1}------------------------------------------------

Image /page/1/Picture/0 description: The image shows a logo for Lake Region Medical. The logo consists of a stylized graphic above the words "Lake Region" in a bold, serif typeface. Below "Lake Region" is the word "Medical" in a smaller, less bold font.

Navilyst Charter 510(k) Application

·

:

{2}------------------------------------------------

:

{3}------------------------------------------------

Image /page/3/Picture/1 description: The image shows the seal of the Department of Health and Human Services (HHS) of the United States. The seal features an abstract image of an eagle with its wings spread, symbolizing protection and strength. The words "DEPARTMENT OF HEALTH & HUMAN SERVICES · USA" are arranged in a circular pattern around the eagle, indicating the department's name and national affiliation.

#### Public Health Service

Food and Drug Administration 10903 New Hampshire Avenue Document Control Room -WO66-G609 Silver Spring, MD 20993-0002

Brivant, LTD. c/o Mr. Tomas Furey Operations Manager Parkmore West Business Park Galway Ireland

MAY 18 2011

Re: K103377

Trade/Device Name: Charter Guidewire Model 45-281, 45-282, 45-283 Regulation Number: 21 CFR 870.1330 Regulation Name: Catheter, Guidewire Regulatory Class: Class II Product Code: DQX Dated: April 14, 2011 Received: April 18, 2011

Dear Mr. Furey:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug. and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA), You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must

{4}------------------------------------------------

Page 2 - Mr. Tomas Furey

comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to http://www.fda.gov/AboutFDA/CentersOffices/CDRH0ffices/ucm115809.htm for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to

http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number [phone] or [phone] or at its Internet address

http://www.fda.gov/MedicalDevices/Resourcesfor You/Industry/default.htm.

Sincerely yours,

C. Tom Zuckerman, M.D.

Bram Zuckerman, M.D Director Division of Cardiovascular Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

{5}------------------------------------------------

#### Indications for Use

K103377 510(k) Number (if known):

Charter Guidewire Device Name:

Indications For Use: Charter Guidewires are intended for use in the coronary and peripheral vasculature.

Contraindications: The Charter Guidewire is not intended for use in the cerebral vasculature. Patients judged not acceptable for percutaneous intervention (PCI).

Prescription Use X (Part 21 CFR 801 Subpart D) AND/OR

Over-The-Counter Use (21 CFR 807 Subpart C)

(PLEASE DO NOT WRITE BELOW LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

(Division Sign-Off)
Division of Cardiovascular Devices

510(K) number K103377